Following the recent decision by NICE (National Institute for Health and Care Excellence) to not fund two Alzheimer’s treatments via the NHS – Leqembi™ (lecanemab) and Kisunla™ (donanemab) – leading brain and mind clinic Re:Cognition Health is ensuring these drugs are accessible through private care at its centres in New Cavendish Street.
The treatments, which target amyloid plaques to slow cognitive decline, are available to eligible patients privately in the UK and through Medicare and supplementary insurance in the United States.
Dr Emer MacSweeney, CEO and Consultant Neuroradiologist at Re:Cognition Health, commented:
“This decision is incredibly disappointing, not only for patients who were hoping to access these treatments on the NHS, but for the momentum of dementia innovation in the UK. However, our private clinics continue to offer these licensed drugs and clinical trials remain a vital route for those who qualify.”
Re:Cognition Health has administered thousands of doses of these medications through its clinical research programme and continues to offer access to late-phase clinical trials free of charge for those meeting eligibility criteria. These trials are open at both UK and US locations and provide an important opportunity for early access to next-generation Alzheimer’s therapies.
The clinic also emphasises the importance of very early diagnosis, as these treatments are most effective in the initial stages of cognitive decline. With a multidisciplinary team of experts in neurology, psychiatry and neuroradiology, Re:Cognition Health provides state-of-the-art cognitive assessment and diagnostic services to identify symptoms before they significantly progress.
“Progress may be delayed, but it hasn’t stopped,” adds Dr MacSweeney. “We urge individuals to seek assessment at the earliest signs of memory concerns. The sooner we act, the greater the opportunity to slow the disease.”
For more information or to enquire about eligibility for treatment or clinical trials, visit www.recognitionhealth.com
